Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2273)

[noa9090]

Hier wurde schon einige Tage nichts mehr reingestellt. Sind den alle schon im Winterschlaf...?

Das waren die letzten News im Dez/Nov.

07.12.2012 Journal Vaccine Reports Novavax' Phase I RSV Nanoparticle Vaccine Candidate Results
http://www.azonano.com/news.aspx?newsID=26130

06.12.2012 Novavax Says Phase I Clinical Trial Paper Published in Journal Vaccine
http://www.benzinga.com/news/12/12/3152945/novavax-says-phas…

03.12.2012 Novavax Publishes Preclinical Study Of RSV Protein Nanoparticle VaccineCandidate
http://www.finanznachrichten.de/nachrichten-2012-12/25352560…

03.12.2012 Novavax (NVAX) Reports Publication of Encouraging Nanoparticle Vaccine Data on RSV
http://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%…

14.11.2012 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production
http://seekingalpha.com/article/1006621-super-novavax-compan…

[noa9090]

After hours -> Innerhalb von 8 Minuten von 2,24$ auf 2,40$ !!!!Wau!!!!

[noa9090]

Top News

Novavax (NVAX) Achieves Primary Objectives in A/H5N1 Phase 1

http://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%…

Novavax, Inc. (Nasdaq: NVAX) today reported positive top-line results from two Phase 1 clinical trials of its A/H5N1 avian influenza vaccine candidate administered alone or with either one of two undisclosed adjuvants. The trials' primary objectives of demonstrating the safety and immunogenicity of varying dose-levels of the vaccine, with and without adjuvant, and the demonstration of statistically significant adjuvant effects on the immune responses were achieved. The vaccine safety was acceptable with no vaccine-related serious adverse events observed.

The two randomized, observer-blind, dose-ranging, placebo-controlled Phase 1 trials were conducted under the company's contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). The primary objectives of the two trials were to demonstrate the safety and immunogenicity of Novavax' VLP-based H5N1 vaccine candidate at varying dose-levels, with and without an adjuvant, using identical clinical study designs but with a different adjuvant in each study. A total of 666 healthy adults 18 to 49 years old were enrolled in the two trials. Each subject received intramuscular injections of vaccine or placebo at day 0 and day 21, and will be followed for 13 months following the first dose. The current data relate to safety and immune responses over the first 42 days.

The adjuvanted vaccines induced strong immunogenicity at all antigen doses tested, including the lowest (3.75 µg) dose, based on hemagglutination inhibition assay (HAI) responses against the vaccine virus at day 42.

88 to 100% of subjects receiving adjuvanted vaccine at all dose levels demonstrated serum HAI titers ≥40, a seroprotection level believed to be associated with reduced risk of disease.
86 to 100% of subjects receiving adjuvanted vaccine at all dose levels demonstrated seroconversion rates with either a four-fold rise in HAI titer or a titer of ≥1:40 from a negative baseline.
Immune responses would fulfill U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) seroprotection and seroconversion criteria for accelerated approval at the lower bound of the 95% confidence level.
When tested against another avian A/H5N1 virus different from that in the vaccine, up to 80% of subjects receiving adjuvanted vaccine developed HAI titers ≥40 against the drifted virus.

[noa9090]

Schlusskurs lag bei 2.39$ -> satter Sprung!!!!!

Stock to Watch: Novavax Up 5.6% (NVAX)

Novavax (NASDAQ:NVAX) is one of today's best performing low-priced stocks, up 5.6% to $2.28 on 2.5x average daily volume. Thus far today, Novavax has traded 1.4 million shares, vs. average volume of 549,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 1.1%) and outperformed the S&P 500 (5.6% to the S&P's 0.9%) during today's trading.

Novavax share prices have moved between a 52-week high of $2.30 and a 52-week low of $1.12 and are now trading 104% above that low price at $2.28 per share. Over the past week, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has declined 0.2%.

Novavax (NASDAQ:NVAX) has potential upside of 132.5% based on a current price of $2.28 and analysts' consensus price target of $5.30. The stock should find initial support at its 50-day moving average (MA) of $2.01 and further support at its 200-day MA of $1.53.

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

SmarTrend recommended that subscribers consider buying shares of Novavax on June 26th, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $1.44. Since that recommendation, shares of Novavax have risen 50.5%. We continue to monitor NVAX for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately

[noa9090]

Update Company Presentation

wurde wohl auf der Stifel Nicolaus Healthcare Conference September 2012 präsentiert...

http://www.novavax.com/download/file/Novavax%20September%202…

[noa9090]

3 Vaccine Companies With Near Term Catalysts

http://seekingalpha.com/article/845621-3-vaccine-companies-w…

1. Novavax (NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle and recombinant nanoparticle vaccine technology, as well as new and efficient manufacturing approaches, the company produces novel vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field.

...

[jostawili123]

Auf www.actiencheck.de ein Hinweis auf Hot Stock Investors, wonach lt. einer Studie von MLV & Co ein Potential von 300%, d.h. 9,50 USD auf Sicht von 12 Monaten besteht.

[noa9090]

Good News from Novavax!!!!!!!

http://www.finanznachrichten.de/nachrichten-2012-07/24130747…

Novavax Says Primary Endpoints Achieved In Phase II Seasonal Influenza Trial

WASHINGTON (dpa-AFX) - Novavax Inc. (NVAX) reported positive top-line results from the company's Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle or VLP vaccine candidate. The study's primary objectives of demonstrating safety and immunogenicity of three ascending dose levels of the quadrivalent influenza vaccine were achieved.

The company said that the VLP vaccine candidate demonstrated immunogenicity against all four viral strains based on hemagglutination inhibition assay (HAI) responses at day 21, was also well-tolerated with no vaccine-related serious adverse events observed and reactogenicity was considered acceptable.

A secondary endpoint of the study was to evaluate the potential of the VLP vaccine to fulfill the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research or CBER criteria for accelerated approval.

In adult populations under 65 years of age, these criteria are based on demonstration of seroconversion rates (the proportion of subjects with a four-fold rise in HAI titer or attaining a titer of >=1:40 from a negative baseline) and seroprotection rates (the proportion of subjects with HAI titers >=1:40 post-vaccination) that are >=40% and >=70%, respectively, at the lower 95% confidence bound.

The company noted that the VLP vaccine candidate exceeded protocol design expectations by fulfilling the FDA seroprotection criterion at the lower 95% confidence bound for all four viral strains included. The VLP vaccine candidate also demonstrated the potential to fulfill the FDA seroconversion criterion by demonstrating >=40% seroconversion against three of four viral strains. The fourth virus, B/Brisbane/60/08, despite fulfilling the seroprotection criterion, failed to meet the seroconversion criterion.

The company also announced completion of enrollment of its two Phase I clinical trials to evaluate the safety and immunogenicity of its monovalent VLP A/H5N1 pandemic influenza vaccine comparing two different adjuvanted vaccine candidates with an unadjuvanted vaccine candidate. Top line data from these trials are expected in the fourth quarter of this year.

The company said it is developing both seasonal and pandemic vaccine candidates under a multi-million dollar contract with BARDA, who has been an active partner in planning and evaluating the development of these products.

Copyright RTT News/dpa-AFX

© 2012 AFX News

[noa9090]

Weitere Artikel über die Zusammenarbeit...

Novavax, PATH sign RSV vaccine clinical development partnership

http://contractresearch.pharmaceutical-business-review.com/n…

Novavax and PATH have signed a clinical development partnership to develop the respiratory syncytial virus (RSV) vaccine.


According to the collaboration, Novavax's Phase II trial scheduled for second half of 2012 will be designed to evaluate the immune response to different doses of the vaccine candidate in women of childbearing age.

PATH will fund approximately $2m on a non-dilutive basis for Novavax's external clinical development costs of the trial.

The recombinant RSV fusion (F) protein vaccine candidate might then be advanced by immunising pregnant women so as to transmit high levels of maternal RSV antibodies to offspring through the placenta before birth thereby providing protection against infection in the early infancy period.

Novavax president and CEO Stanley Erck said the partnership with PATH complements the company's strategy to develop this RSV vaccine for multiple indications in affected patient populations, in all markets throughout the world with multiple partners.

"We estimate that the world-wide market for an RSV vaccine could exceed $5 billion," Erck added.

PATH may then elect to continue to partner with Novavax and provide support for the external clinical development costs through commercialisation for the indication.

Novavax will retain global rights to commercialise the product and considers making the product affordable and available in low-resource countries.

[jostawili123]

Gerade ein Paket über 250.000 Stück zu 2,15US$ über den Tisch gegangen.